Meeting
2015 ASCO Annual Meeting
Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).
Authors
Victoria Meucci Villaflor
University of Chicago Med Ctr, Chicago, IL
Victoria Meucci Villaflor , Ezra E. W. Cohen , James M Melotek , Ryan J Brisson , Theodore Karrison , Elizabeth A. Blair , Louis Portugal , Kerstin Stenson , Jonas A. De Souza , Alexander Langerman , Tanguy Y. Seiwert , Everett E. Vokes , Daniel J. Haraf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT01133678
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6050)
DOI
10.1200/jco.2015.33.15_suppl.6050
Abstract #
6050
Poster Bd #
373
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC.
First Author: Marshall R. Posner
Poster
2019 ASCO Annual Meeting
Randomized phase II study with or without induction chemotherapy combined with accelerated high dose radiotherapy and cetuximab in locally advanced unresectable HPV positive squamous cell carcinoma of the head and neck.
First Author: Signe Friesland
Poster
2014 ASCO Annual Meeting
Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
First Author: Jessica C. Ley
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli